Literature DB >> 29386217

Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.

Dayana B Rivadeneira1,2, Greg M Delgoffe3,2.   

Abstract

With the rapid rise of immunotherapy for cancer treatment, attention has focused on gaining a better understanding of T-cell biology in the tumor microenvironment. Elucidating the factors underlying changes in their function will allow for the development of new therapeutic strategies that could expand the patient population benefiting from immunotherapy, as well as circumvent therapy resistance. Cancers go beyond avoiding immune recognition and inducing T-cell dysfunction through coinhibitory molecules. Recent work has demonstrated that the tumor microenvironment elicits metabolic changes in T cells that dampen their ability to respond and that manipulating these metabolic changes can strengthen an antitumor immune response. Here we review the metabolic status of various types of T cells, the energetic state of the tumor microenvironment, and proposed modalities for improvement of immunotherapy through metabolic remodeling. Clin Cancer Res; 24(11); 2473-81. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29386217      PMCID: PMC5984673          DOI: 10.1158/1078-0432.CCR-17-0894

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  84 in total

Review 1.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

2.  Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation.

Authors:  Valerie A Gerriets; Rigel J Kishton; Amanda G Nichols; Andrew N Macintyre; Makoto Inoue; Olga Ilkayeva; Peter S Winter; Xiaojing Liu; Bhavana Priyadharshini; Marta E Slawinska; Lea Haeberli; Catherine Huck; Laurence A Turka; Kris C Wood; Laura P Hale; Paul A Smith; Martin A Schneider; Nancie J MacIver; Jason W Locasale; Christopher B Newgard; Mari L Shinohara; Jeffrey C Rathmell
Journal:  J Clin Invest       Date:  2014-12-01       Impact factor: 14.808

3.  Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

Authors:  Joseph G Crompton; Madhusudhanan Sukumar; Rahul Roychoudhuri; David Clever; Alena Gros; Robert L Eil; Eric Tran; Ken-Ichi Hanada; Zhiya Yu; Douglas C Palmer; Sid P Kerkar; Ryan D Michalek; Trevor Upham; Anthony Leonardi; Nicolas Acquavella; Ena Wang; Francesco M Marincola; Luca Gattinoni; Pawel Muranski; Mark S Sundrud; Christopher A Klebanoff; Steven A Rosenberg; Douglas T Fearon; Nicholas P Restifo
Journal:  Cancer Res       Date:  2014-11-28       Impact factor: 12.701

Review 4.  PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

Authors:  Egesta Lopci; Ilaria Grassi; Arturo Chiti; Cristina Nanni; Gianfranco Cicoria; Luca Toschi; Cristina Fonti; Filippo Lodi; Sandro Mattioli; Stefano Fanti
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-06-07

5.  The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation.

Authors:  Ruoning Wang; Christopher P Dillon; Lewis Zhichang Shi; Sandra Milasta; Robert Carter; David Finkelstein; Laura L McCormick; Patrick Fitzgerald; Hongbo Chi; Joshua Munger; Douglas R Green
Journal:  Immunity       Date:  2011-12-23       Impact factor: 31.745

Review 6.  Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer.

Authors:  Evan C Lien; Costas A Lyssiotis; Lewis C Cantley
Journal:  Recent Results Cancer Res       Date:  2016

7.  PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine.

Authors:  Brian P Lieberman; Karl Ploessl; Limin Wang; Wenchao Qu; Zhihao Zha; David R Wise; Lewis A Chodosh; George Belka; Craig B Thompson; Hank F Kung
Journal:  J Nucl Med       Date:  2011-11-15       Impact factor: 10.057

8.  Anergic T cells are metabolically anergic.

Authors:  Yan Zheng; Greg M Delgoffe; Christian F Meyer; Waipan Chan; Jonathan D Powell
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

9.  De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells.

Authors:  Luciana Berod; Christin Friedrich; Amrita Nandan; Jenny Freitag; Stefanie Hagemann; Kirsten Harmrolfs; Aline Sandouk; Christina Hesse; Carla N Castro; Heike Bähre; Sarah K Tschirner; Nataliya Gorinski; Melanie Gohmert; Christian T Mayer; Jochen Huehn; Evgeni Ponimaskin; Wolf-Rainer Abraham; Rolf Müller; Matthias Lochner; Tim Sparwasser
Journal:  Nat Med       Date:  2014-10-05       Impact factor: 53.440

10.  Oxygenation to improve cancer vaccines, adoptive cell transfer and blockade of immunological negative regulators.

Authors:  Stephen M Hatfield; Michail Sitkovsky
Journal:  Oncoimmunology       Date:  2015-06-01       Impact factor: 8.110

View more
  26 in total

1.  Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion.

Authors:  Robert D Leone; Liang Zhao; Judson M Englert; Im-Meng Sun; Min-Hee Oh; Im-Hong Sun; Matthew L Arwood; Ian A Bettencourt; Chirag H Patel; Jiayu Wen; Ada Tam; Richard L Blosser; Eva Prchalova; Jesse Alt; Rana Rais; Barbara S Slusher; Jonathan D Powell
Journal:  Science       Date:  2019-11-07       Impact factor: 47.728

2.  Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance.

Authors:  Dayana B Rivadeneira; Kristin DePeaux; Yiyang Wang; Aditi Kulkarni; Tracy Tabib; Ashley V Menk; Padmavathi Sampath; Robert Lafyatis; Robert L Ferris; Saumendra N Sarkar; Stephen H Thorne; Greg M Delgoffe
Journal:  Immunity       Date:  2019-08-27       Impact factor: 31.745

3.  Tumor hypoxia represses γδ T cell-mediated antitumor immunity against brain tumors.

Authors:  Jang Hyun Park; Hyun-Jin Kim; Chae Won Kim; Hyeon Cheol Kim; Yujin Jung; Hyun-Soo Lee; Yunah Lee; Young Seok Ju; Ji Eun Oh; Sung-Hong Park; Jeong Ho Lee; Sung Ki Lee; Heung Kyu Lee
Journal:  Nat Immunol       Date:  2021-02-11       Impact factor: 25.606

4.  ZFP91 disturbs metabolic fitness and antitumor activity of tumor-infiltrating T cells.

Authors:  Feixiang Wang; Yuerong Zhang; Xiaoyan Yu; Xiao-Lu Teng; Rui Ding; Zhilin Hu; Aiting Wang; Zhengting Wang; Youqiong Ye; Qiang Zou
Journal:  J Clin Invest       Date:  2021-10-01       Impact factor: 14.808

5.  P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy.

Authors:  Kelsey M Wanhainen; Changwei Peng; Maggie H Zhou; Bruna de Gois Macedo; Stephen O'Flanagan; Tingyuan Yang; Ameeta Kelekar; Brandon J Burbach; Henrique Borges da Silva; Stephen C Jameson
Journal:  Cancer Immunol Res       Date:  2022-07-01       Impact factor: 12.020

Review 6.  Lactate: The Mediator of Metabolism and Immunosuppression.

Authors:  Yuanyuan Zhang; Zhao Zhai; Jiali Duan; Xiangcai Wang; Jinghua Zhong; Longqiu Wu; An Li; Miao Cao; Yanyang Wu; Huaqiu Shi; Jianing Zhong; Zhenli Guo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

7.  The E3 ubiquitin ligase Peli1 regulates the metabolic actions of mTORC1 to suppress antitumor T cell responses.

Authors:  Chun-Jung Ko; Lingyun Zhang; Zuliang Jie; Lele Zhu; Xiaofei Zhou; Xiaoping Xie; Tianxiao Gao; Jin-Young Yang; Xuhong Cheng; Shao-Cong Sun
Journal:  EMBO J       Date:  2020-11-20       Impact factor: 11.598

8.  Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.

Authors:  Dan P Zandberg; Ashley V Menk; Maria Velez; Daniel Normolle; Kristin DePeaux; Angen Liu; Robert L Ferris; Greg M Delgoffe
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

Review 9.  Integrating the Tumor Microenvironment into Cancer Therapy.

Authors:  Sabina Sanegre; Federico Lucantoni; Rebeca Burgos-Panadero; Luis de La Cruz-Merino; Rosa Noguera; Tomás Álvaro Naranjo
Journal:  Cancers (Basel)       Date:  2020-06-24       Impact factor: 6.639

10.  Metabolic and Immunological Subtypes of Esophageal Cancer Reveal Potential Therapeutic Opportunities.

Authors:  Ryan J King; Fang Qiu; Fang Yu; Pankaj K Singh
Journal:  Front Cell Dev Biol       Date:  2021-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.